Rocket Pharmaceuticals, Inc. (RCKT) Key Metrics
RCKT valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $239.3M
- Enterprise value
- $72.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.9 10-yr median 3.0
- EV / EBITDA
- 24.3
- Dividend yield
- —
- Beta
- 0.50
RCKT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRCKT valuation Price multiples at each fiscal year-end price.
RCKT returns How much profit the business earns on the capital it uses.
RCKT per-share figures Results divided by the shares outstanding at year-end.
RCKT financial health Debt, liquidity and how easily interest is covered.
RCKT valuation history
RCKT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RCKT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RCKT cash returned to shareholders
RCKT price vs earnings per share
RCKT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $390.0M | $1.19B | $2.52B | $1.33B | $1.38B | $3.04B | $1.12B | $583.6M | — | — |
| Enterprise value | $226.0M | $844.9M | $2.17B | $1.00B | $1.01B | $2.62B | $858.8M | $419.3M | — | — |
| Price / book | 1.4 | 2.6 | 5.1 | 2.7 | 3.0 | 6.0 | 3.6 | 3.0 | — | — |
| Earnings yield | −57.2% | −21.7% | −9.8% | −16.6% | −12.2% | −4.8% | −7.5% | −12.8% | — | — |
| Free cash flow yield | −48.8% | −18.1% | −8.4% | −14.0% | −9.3% | −3.4% | −7.9% | −9.5% | — | — |
| Dividend yield | — | — | — | 0.0% | — | 0.2% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.1% | — | — |
| Share price at fiscal year-end | $3.51 | $12.57 | $29.97 | $19.57 | $21.83 | $54.84 | $22.76 | $14.82 | $10.44 | $24.40 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Earnings per share | −$2.01 | −$2.73 | −$2.92 | −$3.26 | −$2.67 | −$2.65 | −$1.70 | −$1.89 | — | — |
| Operating cash flow per share | −$1.71 | −$2.21 | −$2.32 | −$2.61 | −$1.92 | −$1.35 | −$1.32 | −$1.37 | — | — |
| Free cash flow per share | −$1.71 | −$2.27 | −$2.52 | −$2.74 | −$2.04 | −$1.87 | −$1.79 | −$1.40 | — | — |
| Cash per share | $1.70 | $3.93 | $4.44 | $5.23 | $6.15 | $8.72 | $6.21 | $5.22 | — | — |
| Book value per share | $2.49 | $4.89 | $5.86 | $7.19 | $7.19 | $9.09 | $6.27 | $4.93 | — | — |
| Tangible book value per share | $1.92 | $4.21 | $5.10 | $6.23 | $6.70 | $8.54 | $5.64 | $4.15 | — | — |
| Dividends per share | — | — | — | $0.00 | — | $0.10 | — | — | — | — |
| Capex per share | $0.00 | $0.06 | $0.20 | $0.13 | $0.12 | $0.52 | $0.47 | $0.04 | — | — |
| Debt per share | $0.22 | $0.27 | $0.30 | $0.34 | $0.36 | $1.11 | $0.97 | $1.05 | — | — |
| Shares outstanding | 111.1M | 94.8M | 84.0M | 68.1M | 63.2M | 55.4M | 49.0M | 39.4M | — | — |
| Change in shares outstanding | +17.2% | +12.9% | +23.3% | +7.8% | +14.2% | +13.0% | +24.5% | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −60.3% | −54.1% | −50.0% | −47.0% | −35.3% | −36.2% | −33.2% | −61.6% | −48.8% | −47.1% |
| Return on invested capital (ROIC) | −157.3% | −165.5% | −136.5% | −144.8% | −154.5% | −161.4% | −149.7% | −415.7% | — | — |
| Return on assets (ROA) | −52.0% | −47.3% | −43.9% | −42.3% | −31.1% | −30.5% | −26.7% | −42.2% | −25.5% | −35.3% |
| Return on tangible assets | −83.8% | −55.8% | −48.9% | −45.6% | −36.3% | −26.2% | −24.4% | −33.8% | −29.0% | −33.1% |
| Financial health | ||||||||||
| Total debt | $24.9M | $25.5M | $25.0M | $22.9M | $22.6M | $61.7M | $47.4M | $41.4M | $49.5M | $49.0M |
| Cash & short-term investments | $188.9M | $372.3M | $373.2M | $356.4M | $388.7M | $482.7M | $304.1M | $205.7M | $100.0M | $126.5M |
| Net debt | −$164.1M | −$346.8M | −$348.1M | −$333.5M | −$366.1M | −$421.0M | −$256.7M | −$164.3M | −$50.5M | −$77.5M |
| Debt / equity | 0.09 | 0.06 | 0.05 | 0.05 | 0.05 | 0.12 | 0.15 | 0.21 | 1.04 | 0.67 |
| Debt / assets | 0.08 | 0.05 | 0.04 | 0.04 | 0.05 | 0.10 | 0.13 | 0.16 | 0.49 | 0.38 |
| Current ratio | 6.38 | 9.30 | 7.80 | 9.29 | 17.69 | 14.94 | 16.81 | 13.60 | 24.83 | 17.80 |
| Quick ratio | 6.38 | 9.30 | 7.80 | 9.29 | 17.69 | 14.94 | 16.81 | 13.60 | 24.83 | 17.80 |
| Interest coverage | -120.8 | -144.9 | -138.5 | -117.5 | -28.4 | -18.0 | -15.9 | -13.6 | -7.5 | -29.5 |
| Working capital | $162.5M | $337.5M | $329.7M | $324.9M | $369.9M | $454.7M | $289.4M | $193.7M | $97.0M | $121.1M |
| Invested capital | $113.2M | $116.4M | $144.4M | $156.2M | $88.6M | $82.5M | $50.6M | $29.8M | −$2.7M | −$4.3M |
| Tangible asset value | $212.9M | $398.9M | $428.3M | $424.8M | $423.9M | $472.7M | $276.3M | $163.2M | $47.8M | $73.2M |
| Net current asset value | $139.5M | $313.7M | $304.5M | $301.9M | $349.8M | $400.0M | $242.9M | $151.8M | $47.0M | $71.9M |
| Graham net-net per share | $1.22 | $3.25 | $3.56 | $4.32 | $5.48 | $7.14 | $4.88 | $3.77 | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $172,000 | — | $5.6M | — | — | $0 | $155,000 |
| Share buybacks (net) | $67,000 | $0 | $0 | $47,000 | $0 | $72,000 | $0 | $668,000 | $0 | $0 |
| Capex / depreciation | 0.04 | 0.63 | 2.32 | 1.38 | 1.44 | 25.38 | 54.62 | 4.40 | 0.35 | 2.88 |
| Efficiency | ||||||||||
| Days payables outstanding | — | 31.7 | 942.6 | 1,067.8 | 0.0 | 0.2 | 0.4 | 249.7 | 1,827.7 | 3,482.6 |
| Payables turnover | — | 11.53 | 0.39 | 0.34 | 8,159.45 | 1,948.94 | 917.12 | 1.46 | 0.20 | 0.10 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | — | $813,386 | $18.3M | $18.3M | $658 | $588 | $464 | $225,794 | $1.0M | $1.6M |
| Average inventory | — | — | — | — | — | — | — | — | $0 | $0 |
| Intangibles / total assets | 19.5% | 12.2% | 11.4% | 11.8% | 6.2% | 5.2% | 8.3% | 12.3% | 0.0% | 0.0% |
Computed from RCKT's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RCKT valuation and financial ratios
Rocket Pharmaceuticals earned a return on equity of −60.3% and a return on invested capital of −157.3% in fiscal 2025. It ended the year with $24.9 million of debt and $188.9 million in cash and short-term investments, a net cash position of $164.1 million. It returned $0.1 million to shareholders: $0 in dividends and $0.1 million in share buybacks.
See the RCKT income statement, the RCKT chart for price history, or the RCKT stock overview for the latest quote and news.
RCKT key metrics FAQ
What is Rocket Pharmaceuticals's return on equity?
Rocket Pharmaceuticals's return on equity (ROE) was −60.3% in fiscal 2025: net income of -$223.1 million on average shareholders' equity of $370.2 million.
What is Rocket Pharmaceuticals's ROIC?
Rocket Pharmaceuticals's return on invested capital was −157.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals had total debt of $24.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.09 and more cash than debt.
Does Rocket Pharmaceuticals buy back its shares?
Yes. Rocket Pharmaceuticals spent $0.1 million on net share repurchases in fiscal 2025 Shares outstanding changed +17.2% over the year, to 111.1M..
What is Rocket Pharmaceuticals's free cash flow yield?
Rocket Pharmaceuticals generated -$190.5 million of free cash flow in fiscal 2025, a free cash flow yield of −48.8% on its market value at year-end ($390.0 million).
What is Rocket Pharmaceuticals's current ratio?
Rocket Pharmaceuticals's current ratio was 6.38 at the end of fiscal 2025: current assets were 6.38 times current liabilities.